Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas

The present study has analysed the distribution and phenotype of dendritic cells (DCs) in primary cutaneous melanomas and sentinel lymph nodes by immunohistochemistry. In primary melanomas, an increase of DCs was found in the epidermis and the peritumoural area. Intraepidermal DCs were mostly CD1a+/Langerin+ Langerhans cells. Peritumoural DCs included a large population of DC‐SIGN+/mannose‐receptor+/CD1a− DCs, a small subset of CD1a+ DCs, and, remarkably, plasmacytoid monocytes/plasmacytoid DCs (PM/PDCs). The PM/PDCs, most likely recruited by SDF‐1 secreted by melanoma cells, produced type I interferon (IFN‐I), but the expression of the IFN‐α inducible protein MxA was extremely variable and very limited in the majority of cases. All DC subsets were predominantly immature. The peritumoural area also contained a minor subset of mature CD1a+ DCs. However, the small amount of local interleukin (IL)‐12 p40 mRNA and the naïve phenotype of 20–50% of peritumoural T‐lymphocytes are consistent with poor T‐cell stimulation or erroneous recruitment. In sentinel lymph nodes, notable expansion of mature CD1a+/Langerin+ DCs was observed. The paucity of intratumoural DCs and the predominant immature phenotype of peritumoural dermal DCs indicate defective maturation of primary cutaneous melanoma‐associated DCs, resulting in lack of T‐cell priming. These results may explain why melanoma cells grow despite the presence of infiltrating immune cells. Copyright © 2003 John Wiley & Sons, Ltd.

[1]  T. Blankenstein,et al.  Cross-priming versus cross-tolerance: are two signals enough? , 2002, Trends in immunology.

[2]  Antonio Lanzavecchia,et al.  BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction , 2001, The Journal of experimental medicine.

[3]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[4]  L. Adorini,et al.  Cutting Edge: Selective Usage of Chemokine Receptors by Plasmacytoid Dendritic Cells1 , 2001, The Journal of Immunology.

[5]  F. Lund-Johansen,et al.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. , 2001, The American journal of pathology.

[6]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[7]  M. Jefford,et al.  The use of dendritic cells in cancer therapy. , 2001, The Lancet. Oncology.

[8]  M. Carrington,et al.  A Dendritic Cell–Specific Intercellular Adhesion Molecule 3–Grabbing Nonintegrin (Dc-Sign)–Related Protein Is Highly Expressed on Human Liver Sinusoidal Endothelial Cells and Promotes HIV-1 Infection , 2001, The Journal of experimental medicine.

[9]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[10]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[11]  F. Lund-Johansen,et al.  Experimentally Induced Recruitment of Plasmacytoid (CD123high) Dendritic Cells in Human Nasal Allergy1 , 2000, The Journal of Immunology.

[12]  A. Lanzavecchia,et al.  Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization , 2000, Nature Immunology.

[13]  Carl G. Figdor,et al.  DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking , 2000, Nature Immunology.

[14]  D. Rigel,et al.  Malignant melanoma: Prevention, early detection, and treatment in the 21st century , 2000, CA: a cancer journal for clinicians.

[15]  C. Figdor,et al.  Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses , 2000, Cell.

[16]  S Gordon,et al.  Macrophage lectins in host defence. , 2000, Microbes and infection.

[17]  P. Dalerba,et al.  Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[19]  J. Banchereau,et al.  In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas , 1999, The Journal of experimental medicine.

[20]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[21]  Rong-Fu Wang,et al.  Human tumor antigens: implications for cancer vaccine development , 1999, Journal of Molecular Medicine.

[22]  J. Banchereau,et al.  The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface , 1999, European journal of immunology.

[23]  D. Jarrossay,et al.  Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.

[24]  W. Vermi,et al.  Plasmacytoid monocytes express IL3‐receptor alpha and differentiate into dendritic cells , 1999, Histopathology.

[25]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[26]  N. Yawalkar,et al.  Characterization of human skin-derived CD1a-positive lymph cells , 1999, Archives of Dermatological Research.

[27]  J. Banchereau,et al.  A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. , 1998, Immunity.

[28]  T. Yoshino,et al.  Heterogeneity of dendritic cells in human superficial lymph node: in vitro maturation of immature dendritic cells into mature or activated interdigitating reticulum cells. , 1998, The American journal of pathology.

[29]  C. Caux,et al.  Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites , 1998, The Journal of experimental medicine.

[30]  F. Nestle,et al.  Human dermal dendritic cells process and present soluble protein antigens. , 1998, The Journal of investigative dermatology.

[31]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[32]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[33]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[34]  C Caux,et al.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. , 1997, Blood.

[35]  J. Banchereau,et al.  The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand , 1997, The Journal of experimental medicine.

[36]  J. Banchereau,et al.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha , 1996, The Journal of experimental medicine.

[37]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[38]  D. Fivenson,et al.  Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis , 1995, Journal of cutaneous pathology.

[39]  M. Fey,et al.  Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders. , 1995, Blood.

[40]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Thompson,et al.  Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.

[42]  G. Schuler,et al.  Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. , 1993, The Journal of clinical investigation.

[43]  A. Cochran,et al.  Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. , 1993, The Journal of investigative dermatology.

[44]  G. Halliday,et al.  Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. , 1991, The Journal of investigative dermatology.

[45]  B. Nickoloff,et al.  Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin , 1989, The British journal of dermatology.

[46]  V. Desmet,et al.  Anti-high endothelial venule monoclonal antibody HECA-452 recognizes plasmacytoid T cells and delineates an "extranodular" compartment in the reactive lymph node. , 1989, Immunology letters.

[47]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[48]  V. Desmet,et al.  Plasmacytoid T cells. Immunohistochemical evidence for their monocyte/macrophage origin. , 1988, The American journal of pathology.

[49]  V. Desmet,et al.  Plasmacytoid T cells: a cell population normally present in the reactive lymph node. An immunohistochemical and electronmicroscopic study. , 1988, Human pathology.

[50]  A. Cochran,et al.  Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. , 1988, The Journal of investigative dermatology.

[51]  D. Mason,et al.  Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas , 2004, Virchows Archiv A.

[52]  G. Schuler,et al.  The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system , 2004, Springer Seminars in Immunopathology.

[53]  S. Imamura,et al.  CD 34 + Hematopoietic Progenitors from Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to GM-CSF + TNFoL , 2003 .

[54]  J. Davoust,et al.  Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. , 2000, Immunity.

[55]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[56]  A. Palangié,et al.  Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. , 1995, Invasion & metastasis.

[57]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[58]  P. Staeheli Interferon-induced proteins and the antiviral state. , 1990, Advances in virus research.